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HIV causes a chronic infection by evading immune eradication. A key element of HIV immune escape is the HIV-1 Nef
protein. Nef causes a reduction in the level of cell surface major histocompatibility complex class I (MHC-I) protein
expression, thus protecting HIV-infected cells from anti-HIV cytotoxic T lymphocyte (CTL) recognition and killing. Nef also
reduces cell surface levels of the HIV receptor, CD4, by accelerating endocytosis. We show here that endocytosis is not
required for Nef-mediated downmodulation of MHC-I molecules. The main effect of Nef is to block transport of MHC-I
molecules to the cell surface, leading to accumulation in intracellular organelles. Furthermore, the effect of Nef on MHC-I
molecules (but not on CD4) requires phosphoinositide 3-kinase (PI 3-kinase) activity. We propose that Nef diverts MHC-1
proteins into a PI 3-kinase-dependent transport pathway that prevents expression on the cell surface. © 2001 Academic Press
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While cytotoxic T lymphocytes are important in initially
controlling HIV infection, they fail to eradicate it. The
reasons for this are complex (Collins and Baltimore,
1999) and include the fact that HIV reduces the cell
surface expression of major histocompatibility complex
class I (MHC-I) molecules on infected cells (Collins et al.,
1998; Kerkau et al., 1989; Mangasarian et al., 1999;
Schwartz et al., 1996). HIV-mediated MHC-I protein
downmodulation makes infected cells more resistant to
CTL recognition and lysis (Collins et al., 1998), and HIV-1
nef is responsible for the effects of HIV on MHC-I protein
expression (Collins et al., 1998; Greenberg et al., 1998b;
Mangasarian et al., 1999; Schwartz et al., 1996).
HIV-1 Nef is a 27-kDa multifunctional protein which is
not required for viral replication in vitro, but is required
for the development of AIDS in vivo (Baba et al., 1999;
Greenough et al., 1999; Kestler et al., 1991; Kirchoff et al.,
995; Learmont et al., 1999). Nef has no known enzymatic
ctivity and is hypothesized to act as an adaptor mole-
ule that tethers cellular proteins together in unusual
ays. Thus, it creates a cellular environment hospitable
or viral growth. For example, Nef promotes virus produc-
ion by removing cell surface CD4 that can interfere with
irus release (Bour et al., 1999; Lama et al., 1999; Ross et
1 Present address: Syntonix Pharmaceuticals Inc., Waltham, MA
2451.
2 To whom correspondence and reprint requests should be ad-
dressed at 4301 MSRB III, Box 0638, 1150 West Medical Center Drive,
Ann Arbor, MI 48109. Fax: (734) 763-7672. E-mail: klcollin@umich.edu.
267l., 1999). To accomplish this, Nef is reported to promote
he association of CD4 with adaptins, a vacuolar ATPase,
ymphocyte-specific protein tyrosine kinase (LCK), and
b-coat protein (b-COP). These interactions lead to endo-
cytosis and targeting of CD4 to lysosomes (Benichou et
al., 1994; Bresnahan et al., 1998; Craig et al., 1998; Green-
berg et al., 1997, 1998a; Le Gall et al., 1998; Lu et al., 1998;
iguet et al., 1998, 1999).
Based on mutagenesis data from a number of groups,
vidence has accumulated suggesting that nef down-
odulates MHC-I and CD4 proteins by distinct mecha-
isms. MHC-I protein downmodulation requires the first
roline-rich region and an N-terminal region (amino ac-
ds 17–26 of Nef), which are not required for CD4 down-
odulation (Greenberg et al., 1998b; Mangasarian et al.,
999). Furthermore, a dileucine motif is required for Nef’s
ffects on CD4, but is not required for MHC-I protein
ownmodulation (Bresnahan et al., 1998; Craig et al.,
998; Greenberg et al., 1998a,b; Mangasarian et al., 1999;
iggs et al., 1999).
In the presence of Nef, MHC-I molecules traffic into
he early Golgi apparatus normally (Schwartz et al.,
996). It is not known, however, if they traffic normally
rom the Golgi apparatus to the cell surface. In fact,
HC-I molecules are reported to accumulate in the
rans-Golgi network (TGN) and in post-Golgi clathrin con-
aining vesicles of Nef-expressing cells (Greenberg et
l., 1998b; Le Gall et al., 1998; Piguet et al., 2000). Exper-
iments using exogenously applied antibodies to MHC-I
proteins suggest that some Golgi targeting occurs by
endocytosis of molecules on the cell surface (Greenberg
et al., 1998b; Le Gall et al., 1998; Piguet et al., 2000).
0042-6822/01 $35.00
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268 SWANN ET AL.However, this does not exclude the possibility that most
of the MHC-I molecules are retained inside the cell.
Here we have specifically examined the effect of Nef
on the trafficking of MHC-I molecules from the Golgi
apparatus to the plasma membrane and have found it to
be disrupted. Furthermore, a complete block of clathrin-
mediated endocytosis did not affect Nef-mediated MHC-I
protein downmodulation. We also found that loss of cell
surface MHC-I protein expression was completely de-
pendent on phosphoinositide 3-kinase (PI 3-kinase) ac-
tivity. In contrast, Nef-mediated CD4 downmodulation did
not require this activity. These data indicate that,
whereas Nef mediates downmodulation of CD4 by ac-
celerating endocytosis and degradation, Nef affects
MHC-I molecules by blocking transport to the cell sur-
face via a PI 3-kinase-dependent pathway.
RESULTS
Nef promotes accumulation of MHC-I molecules in
intracellular organelles
To protect against both CTL and natural killer cell lysis,
HIV-1 Nef downmodulates HLA-A and B, but not C (Le
Gall et al., 1998) or E proteins (Cohen et al., 1999).
ecause most antibody reagents reactive against MHC-I
roteins do not differentiate among these allotypes, we
sed a tagged version of MHC-I HLA-A2 protein in which
FP is fused to the N-terminal, extracellular region
EGFP/A2). Thus, it is separated from the cytoplasmic
omain which contains residues important for Nef’s ac-
ivities. In transfected cells, EGFP/A2 was efficiently de-
ivered to the secretory pathway, formed a complex with
ight chain b2-microglobulin, and reacted with W6/32, a
onoclonal antibody specific for b2-microglobulin-com-
lexed heavy chains (data not shown). Furthermore,
FIG. 1. Nef downmodulates cell surface EGFP/A2. 373 mg cells were
treated with adeno-Nef (nef1) or adenovector (nef2; 1:20,000 particles/
ell). Twenty-four hours later, cells were harvested and stained with an
ntibody directed against GFP. Fluorescence due to anti-GFP staining
s shown. The negative control for staining is 373 mg cells that do not
xpress EGFP/A2 (black line). The curve for cells expressing adeno-m
w
ef is represented by the gray line. The curves for cells expressing
denovector and for untreated cells are almost exactly superimposed.GFP/A2 was stably expressed to high levels on the
urface of transfected cells (Fig. 1). Finally, in agreement
ith what others have reported (Greenberg et al., 1998b;
e Gall et al., 1998; Piguet et al., 2000), Nef-expressing,
IV-infected astrocytic cells accumulated EGFP/A2 in
he perinuclear region (Fig. 2). Astrocytic cells were cho-
en for these experiments because they are large cells
ith abundant cytoplasm amenable to fluorescence mi-
roscopy. Furthermore, they are a normal target of HIV
nfection in vivo.
We obtained the same results when Nef was introduced
sing an adenovirus vector system (which was higher titer
nd infected all the cells). Cells expressing Nef downmodu-
ated cell surface EGFP/A2 by flow cytometry (Fig. 1) and
nduced an accumulation of MHC-I molecules in the region
f the Golgi apparatus (Fig. 3). As reported by others, MHC-I
olocalized partially with a Golgi marker [(Le Gall et al.,
998), Fig. 3D, areas of colocalization appear yellow in
hese images]. Treatment of these cells with brefeldin A, a
ungal toxin that causes disassembly of the Golgi appara-
us, dispersed most of the EGFP/A2 throughout the interior
f cells expressing Nef (data not shown). Thus, these data
re consistent with relocalization of MHC-I molecules to the
olgi apparatus and possibly other intracellular vesicles in
ef-expressing cells. We were able to obtain little evidence
or preferential shuttling of MHC-I to the lysosomes in
ef-expressing cells. Steady state levels of endogenous
HC-I protein and EGFP/A2 were not affected by Nef
xpression as assessed by Western blot or flow cytometric
nalysis of total cellular MHC-I protein (data not shown).
urthermore, a pulse-chase analysis of endogenous and
agged MHC-I molecules revealed only a small (approxi-
FIG. 2. HIV-infected 373 mg cells expressing EGFP/A2 have reduced
surface expression of EGFP/A2 protein and localize GFP to the perinu-
clear region. 373 mg cells expressing EGFP/A2 were infected with HIV,
stained with anti-PLAP antibodies, and analyzed by confocal micros-
copy. The outer surfaces of infected cells are stained in this image.ately 12%) decrease in the half-life of these molecules
hen Nef was expressed (data not shown).
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269HIV-1 NEF BLOCKS TRANSPORT OF MHC CLASS I MOLECULESHIV-1 Nef protein blocks transport of MHC-I
molecules to the cell surface
To determine whether Nef expression causes MHC-I
molecules to be retained inside the cell, we utilized the
fact that trafficking through the secretory pathway can be
blocked in the Golgi apparatus by reducing the temper-
ature to 20°C for several hours. After transfer to 37°C,
cell surface proteins traffic to the plasma membrane
within 30 min (Matlin and Simons, 1983). Indeed, a 20°C
incubation arrested EGFP/A2 transport in perinuclear
regions of control cells (Fig. 4, nef2, 0 min). As expected,
hen these cells were shifted to 37°C, EGFP/A2 moved
nto the cell surface (Fig. 4, nef2, 30–60 min). However,
when cells expressing Nef were blocked and released,
EGFP/A2 was not transported to the cell surface (Fig. 4,
nef1). To better appreciate the intracellular localization of
GFP/A2 in these cells, the surface was stained red by
reatment with fluorescently labeled concanavalin A (con
). These data support the model that the major effect of
ef is to retain MHC-I molecules within intracellular
esicles and that endocytosis from the cell surface is not
FIG. 3. Nef directs EGFP/A2 to the region of the Golgi apparatus. 37
r adenovector (nef2, A–C; 1:20,000 particles/cell). The cells were stain
Materials and Methods. In the overlay panels, yellow coloration repre
GFP fluorescence.equired for loss of cell surface expression. This result
as highly reproducible and occurred when Nef was
t
rntroduced using either adenovirus or retrovirus (data not
hown).
To demonstrate that intracellular retention of EGFP/A2
y Nef was specific, we examined Nef and MHC-I pro-
ein mutants. Mutation of a proline-rich region of Nef
reviously shown to be required for MHC-I downmodu-
ation disrupted Nef-mediated intracellular retention
Greenberg et al., 1998b) (Fig. 5A). This mutant was not
ompletely inactive, because it caused EGFP/A2 to
each the cell surface somewhat more slowly than in
ontrol cells (Fig. 5A). In addition, mutation of a tyrosine
esidue in EGFP/A2, which was previously shown to be
equired for Nef’s effects, also disrupted Nef-mediated
ntracellular retention (Greenberg et al., 1998b; Le Gall et
l., 1998) (Fig. 5B). Western blot analysis revealed that
he decreased Nef effect in these mutant cell lines was
ot due to decreased expression of Nef protein (Fig. 5C).
Dominant negative mutants of dynamin which block
ndocytosis do not affect Nef-mediated MHC-I protein
ownmodulation. Dynamin is a member of a family of
TPases that is required for endocytosis. It is specifically
ells expressing EGFP/A2 were transduced with adeno-Nef (nef1, D–F)
BODIPY TR ceramide to stain the Golgi apparatus as described under
cations where with BODIPY TR ceramide fluorescence overlaps with3 mg c
ed withargeted to coated pits at the plasma membrane and is
equired for coated vesicle budding. Dominant negative
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270 SWANN ET AL.forms of this molecule (dynamin K44A) block clathrin-
mediated endocytosis at a stage after coat assembly
(van der Bliek et al., 1993). Our data, that Nef blocks
ransport of MHC-1 protein to the cell surface, would
ndicate that endocytosis is not required for targeting of
HC-I molecules to the Golgi. Thus, Nef should down-
odulate MHC-I molecules in cells that express domi-
ant negative dynamin K44A.
To test this hypothesis, we transfected A2/EGFP into
ells that express dynamin K44A under an inducible
romoter regulated by tetracycline (Damke et al., 1994)
nd then introduced Nef or a control vector. As shown in
ig. 6A, we found that Nef-dependent intracellular local-
zation of EGFP/A2 was unaffected by expression of
ynamin K44A. We also failed to detect any effect of
ynamin K44A expression on wild-type MHC-I protein
ownmodulation by Nef as assayed by flow cytometry
data not shown). To ensure that these cells were behav-
ng as expected, we showed that endocytosis of trans-
errin by the transferrin receptor was completely blocked
n these cells (Fig. 6B). Furthermore, we confirmed that
ynamin K44A protein expression was upregulated ap-
ropriately (Fig. 6C). To ensure that this result was not
nique to EGFP/A2, we also stained the cells for endog-
nous MHC-I class I HLA-A2 protein. We observed re-
ults that were identical to those obtained with the fusion
rotein (data not shown).
he effect of Nef on MHC-I molecules is blocked by
n inhibitor of PI 3-kinase
Proteins that regulate intracellular trafficking and that
FIG. 4. Nef expression leads to retention of MHC-I molecules in intra
deno-Nef (nef1) as indicated, incubated at 20°C for 5 h to block prot
nalysis by confocal fluorescence microscopy. Images were collected
made by projecting all Z series images into one. The “no block” contro
To demarcate the outline of the cells, samples were treated with flu
instructions.nteract with Nef are candidates for cellular effectors of Nef
ctivity. For example, PI 3-kinase is essential for the proper
m
Wntracellular localization of the cation-independent man-
ose-6-phosphate receptor (ci-M6PR) (Brown et al., 1995;
avidson, 1995; Gaffet et al., 1997), and PI 3-kinase is
eported to interact with Nef (Graziani et al., 1996; Kim et al.,
999). To test whether PI 3-kinase is required for Nef’s
ffects on MHC-I molecules, we treated cells with
Y294002, a specific inhibitor of PI 3-kinase (Vlahos et al.,
994). This agent blocked the ability of Nef to sequester
HC-I molecules (Fig. 7, top). The effects of LY294002 on
ef was not due to inhibition of adenoviral infection, be-
ause a control adenovirus expressing alkaline phospha-
ase was not affected by this inhibitor (Fig. 7, middle). In
ddition, a Western blot revealed that equivalent amounts
f Nef protein were expressed in cells treated with the
nhibitor (Fig. 7, bottom).
LY294002 also dramatically inhibited downmodulation
f wild-type HLA-A2 protein as assayed by flow cytom-
try (Fig. 8, top), and this was not due to a reduction in
ef protein levels (Fig. 8, middle). In contrast, the inhib-
tor had no effect on Nef-mediated CD4 downmodulation
Fig. 8, bottom). These data demonstrate a role for PI
-kinase in Nef-mediated MHC-I protein downmodula-
ion and provide strong evidence that Nef reduces the
ell surface expression of MHC-I protein and CD4 by
istinct mechanisms.
DISCUSSION
ef-induced intracellular retention of MHC-I
olecules
Our studies demonstrate that Nef’s effects on MHC-I
r organelles. 373 mg cells were transduced with adenovector (nef2) or
sport in the Golgi, shifted to 37°C, and fixed at the indicated time for
series using 0.5-mm steps. The final projected image shown here was
ents cells that were kept at 37°C during the entire incubation period.
ntly labeled concanavalin A (con A) according to the manufacturerscellula
ein tran
as a Z
l represolecules and CD4 occur by different mechanisms.
hile Nef promotes the loss of cell surface CD4 by
ws
s
k of Nef
L in cells
271HIV-1 NEF BLOCKS TRANSPORT OF MHC CLASS I MOLECULESaccelerated endocytosis, lysosomal targeting, and deg-
radation, we demonstrate that Nef affects MHC-I mole-
cules primarily by blocking transport to the cell surface.
Our experiments made use of an MHC-I-GFP fusion
protein which allowed us to specifically follow the trans-
port of the HLA-A2 allotype of MHC-I and avoided the
use of exogenously applied antibodies that might disrupt
its trafficking. The behavior of the fusion protein was
identical to the behavior of native MHC-I protein as
FIG. 5. (A) Efficient retention of MHC-I molecules by HIV-1 Nef requir
ere transduced with adenovector (nef2), or a mutant version of adeno
at 20°C for 5 h to block protein transport in the Golgi, shifted to 37°C, an
Images were collected as a Z series using 0.5-mm steps. The final proje
The no block control represents cells that were kept at 37°C during th
Nef requires tyrosine 320 in the HLA-A2 cytoplasmic tail. 373 mg cells
with adeno-Nef (nef1) or adenovector (nef2). The next day, the cells we
hifted to 37°C, and fixed at the indicated time for analysis by confocal
teps. The final projected image shown here was made by projecting
ept at 37°C during the entire incubation period. (C) Equivalent amounts
ane 2, mutant adeno-Nef (P72A, P75A); Lane 3; wild-type adeno-Nefdetailed in three prior reports describing the effects of
Nef on MHC-I protein. Specifically, it accumulated intra-cellularly in the region of the Golgi apparatus only when
it had an intact cytoplasmic tail tyrosine residue and only
when Nef had an intact proline-rich region (Greenberg et
al., 1998b; Le Gall et al., 1998; Piguet et al., 2000). Fur-
thermore, we have shown that the tagged version be-
haved identically to endogenous MHC-1 protein in that
Nef did not dramatically alter its half-life. Finally, the
effect of Nef on both endogenous and tagged MHC-I
protein was not blocked by dominant negative dynamin
tact SH3 binding domain. 373 mg cells expressing wild-type EGFP/A2
ef1 (P72A, P75A)] as indicated. The next day, the cells were incubated
at the indicated time for analysis by confocal fluorescence microscopy.
age shown here was made by projecting all Z series images into one.
e incubation period. (B) Intracellular retention of MHC-I molecules by
sing wild-type EGFP/A2 or mutant EGFP/A2 (Y320A) were transduced
bated at 20°C for 5 h to block protein transport in the Golgi apparatus,
cence microscopy. Images were collected as a Z series using 0.5-mm
ries images into one. The no block control represents cells that were
protein were produced in these cell lines. Lane 1, wild-type adeno-Nef;
expressing EGFP/A2 (Y320A).es an in
-Nef [n
d fixed
cted im
e entir
expres
re incu
fluores
all Z sebut was disrupted by inhibitors of PI 3-kinase.
We used two approaches to distinguish whether the
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272 SWANN ET AL.major effect of Nef was to block transport to the cell
surface or to induce endocytosis and retrograde trans-
port from the plasma membrane. First, we directly ob-
served transport in cells synchronized with a tempera-
ture block and found that Nef expression caused MHC-I
to remain within intracellular organelles. Second, we
demonstrated that clathrin-dependent endocytosis and
retrograde transport was not required for Nef-mediated
MHC-I downmodulation. This was accomplished by
FIG. 6. Endocytosis is not required for Nef’s effects on MHC-I mol-
cules. HeLa cells overexpressing a dominant negative form of dy-
amin (K44A) were transfected with EGFP/A2, transduced as indicated
ith adeno-Nef (nef1) or adenovector (nef2), and harvested 48 h later.
o induce dynamin K44A, tetracycline was removed from the indicated
ample at the time of transduction. (A) Harvested cells were fixed and
xamined for EGFP/A2 expression. (B) Control cells transfected with
GFP/A2 were stained with transferrin–Texas Red conjugate as de-
cribed under Materials and Methods to demonstrate that endocytosis
y the transferrin receptor was completely blocked under the condi-
ions of our assay. These cells were visualized with a 603 objective
rather than 1003 in A) so that more cells could be displayed. (C)
estern blot analysis of dynamin and Nef protein expression levels in
ells from A.demonstrating that MHC-I downmodulation occurred
normally in a cell line that expressed dominant negativedynamin K44A and was therefore defective at clathrin-
mediated endocytosis.
Previous studies have reported that Nef promotes the
endocytosis and transport of antibody-bound MHC-I pro-
tein complexes from the plasma membrane to the Golgi
apparatus (Greenberg et al., 1998b; Le Gall et al., 1998).
However, these reports did not examine whether newly
synthesized MHC-I protein was transported from the
FIG. 7. (Top) Inhibitors of PI 3-kinase block the effects of Nef. 373 mg
cells expressing EGFP/A2 were transduced with adeno-Nef (nef1) or
denovector (nef2; 1:20,000 particles/cell). 70-mM LY294002 or its sol-
vent, DMSO, were added to the indicated cells immediately following
adenoviral transduction. Approximately 18 h later, cells were harvested,
fixed, and analyzed by confocal fluorescence microscopy. (Middle)
LY294002 does not block adenovirus transduction. 373 mg cells ex-
pressing EGFP/A2 were transduced with an adenoviral vector express-
ing alkaline phosphatase (1:20,000 particles/cell). The indicated cells
were treated with 70-mM LY294002 or its solvent and stained to assess
lkaline phosphatase activity. (Bottom) LY294002 does not inhibit Nef
rotein expression. 373 mg cells transduced with the indicated virus
1:20,000 particles/cell) were treated with 70-mM LY294002 or its sol-
vent, DMSO, or were left untreated. Equal amounts of cellular proteins
were electrophoresed, blotted onto Immobilon, and probed with an
antibody directed against Nef. Lane 1, untreated; Lane 2, cells treated
with solvent; Lane 3, cells treated with LY294002.
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273HIV-1 NEF BLOCKS TRANSPORT OF MHC CLASS I MOLECULESGolgi to the cell surface. Taking all of the data together,
we conclude that endocytosis and retrograde transport
contribute in a minor way to the removal of MHC-I mol-
ecules from the surface of Nef-expressing cells, whereas
Nef acts chiefly by blocking transport of MHC-I mole-
cules to the cell surface. Further work is needed to
determine whether MHC-I molecules remain within the
Golgi apparatus or travel into other intracellular compart-
FIG. 8. (Top) LY294002 blocks the effects of Nef on wild-type MHC
adenovector (nef2; 1:25,000 particles/cell for the DMSO control; 1:50,000
8 h, cells were harvested and stained with a monoclonal antibody direc
urve represents fluorescence from cells stained with a matched negati
n inhibitor- and mock-treated cells. Equal amounts of cellular proteins
irected against HIV-1 Nef. (Bottom) LY294002 does not block the e
ransduced with adeno-Nef or adenovector. After approximately 18 h, c
D4 and analyzed by flow cytometry. The filled in black curve is stainments.
While this manuscript was in preparation, Le Gall andcolleagues reported similar conclusions (Le Gall et al.,
2000). They also used dominant negative dynamin K44A
to demonstrate that Nef did not require endocytosis to
downmodulate MHC-I protein, whereas endocytosis was
required for downmodulation of CD4.
Le Gall and colleagues also demonstrated that the
required tyrosine residue in the cytoplasmic tail of MHC-I
does not form a cryptic endocytosis signal that is un-
-A2 protein. 373 mg cells were transduced with adeno-Nef (nef1) or
es/cell for cells treated with 75 mM of the inhibitor). After approximately
inst HLA-A2 protein and analyzed by flow cytometry. The filled in black
rol antibody. (Middle) Equivalent amounts of Nef protein are expressed
lectrophoresed, blotted onto Immobilon, and probed with an antibody
f Nef on CD4 downmodulation. 373 mg cells expressing CD4 were
re harvested and stained with a monoclonal antibody directed against
he parent CD4-negative cell line with anti-CD4 antibody.-I HLA
particl
ted aga
ve cont
were e
ffects omasked in the presence of Nef (Le Gall et al., 2000).
Further experiments are needed to determine the actual
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274 SWANN ET AL.role of the cytoplasmic tail in Nef-mediated MHC-I pro-
tein downmodulation. It is possible that the tail under-
goes differential phosphorylation or protein–protein in-
teractions in the presence of Nef that disrupt the normal
trafficking of MHC-I protein in the Golgi apparatus.
The role of PI 3-kinase in Nef-mediated MHC-I
protein downmodulation
The effect of Nef on MHC-I molecules (but not CD4)
was blocked by a PI 3-kinase inhibitor. Because there
are multiple forms of PI 3-kinase that influence cell sig-
naling and intracellular trafficking, more work will be
required to understand the role of PI 3-kinase in Nef-
mediated MHC-I protein downmodulation. However, be-
cause expression of Nef directs MHC class I to the TGN
and to vesicles containing clathrin and g-adaptin (Green-
berg et al., 1998b; Le Gall et al., 1998), it is interesting to
ote that an as yet unidentified form of PI 3-kinase
egulates transport of ci-M6PR to these locations (Brown
t al., 1995; Davidson, 1995; Gaffet et al., 1997). ci-M6PR
s a protein which carries lysosomal hydrolases from the
GN to the endosomal and prelysosomal compartments
nd then returns to the TGN for another round. PI 3-ki-
ase activity is required to promote sorting of ci-M6PR
rom the Golgi apparatus into clathrin- and g-adaptin-
containing vesicles destined for the early endosomal
compartment. In the presence of PI 3-kinase inhibitors,
transport of ci-M6PR is disrupted and its ligand, cathep-
sin D, is secreted into the media (Gaffet et al., 1997).
Thus, the observations we and others have made sug-
gest that Nef may divert MHC-I protein into a pathway
similar to that normally followed by ci-M6PR.
Nef has recently been reported to interact with PACS-1
through an acidic region that is required for Nef-medi-
ated MHC-I protein downmodulation (Piguet et al., 2000).
n this study anti-sense to PACS-I partially blocked the
ffects of Nef on MHC-I protein downmodulation and
uggested that PACS-I plays a role in this pathway. The
ormal function of PACS-I is to bind specific cargo and
romote recycling of endocytic and Golgi-derived vesi-
les containing that cargo back to the Golgi apparatus
Wan et al., 1998). It has been hypothesized that PACS-I
orms a complex containing Nef and MHC-1 protein,
hich promotes recycling of MHC-I protein to the Golgi
pparatus. PACS-I normally affects furin which is trans-
orted from the TGN in clathrin-coated vesicles. Thus,
ne possible model that would incorporate all observa-
ions is that PI 3-kinase-dependent sorting of MHC-I into
lathrin-coated vesicles from the TGN is a necessary
irst step that is followed by PACS-I-dependent vesicle
ecycling.
We have found that the major effect of Nef is to disrupt
he transport of MHC-I molecules to the plasma mem-
rane. Thus, the critical cell surface epitopes required for
TL recognition and lysis are sequestered inside the cellnd cannot induce cell killing. We have also shown that
I 3-kinase is an important component of Nef-mediated
HC-I protein sequestration. This information may allow
he development of therapeutic measures that can dis-
upt the effect of Nef and restore immune protection to
eople infected with HIV.
MATERIALS AND METHODS
ell lines and DNA expression constructs
The astrocytoma cell line 373 mg, pcDNA-HLA-A2, and
ntibody to b-2-microglobulin were provided by Dr.
Hidde Ploegh’s laboratory at Harvard Medical School. A
construct expressing the VSV-G protein used for HIV
pseudotyping was provided by Dr. Nancy Hopkins at MIT.
A construct expressing CD4 (PSVT4) was obtained from
Ben Chen at M.I.T. A cell line that expresses dynamin
K44A under a tetracycline-inducible promoter (Damke et
al., 1994) was provided by Sandra Schmid at The Scripps
Research Institute.
Construction of an HLA-A2 GFP fusion protein
EGFP was PCR-amplified from the vector pEGFP.C1
(Clontech, Palo Alto, CA) using the primers egfpN-f [GG-
CAGCATGGTGAGCAAGGGCGAGGAGCTGTTCACC] and
egfpC-f [GCCTCCCCCGCCGCCCTTGTACAGCTCGTC-
CATGCCGAGAGT-GATCCC]. This EGFP is a red-shifted ver-
sion of the green fluorescent protein with point mutations
from the wild-type resulting in phe-64-leu and ser-65-thr
(Cormack et al., 1996). It is also optimized for mammalian
codon usage (Haas et al., 1996). The egfpN-primer encodes
an additional glycine serine at the signal peptide cleavage
point, which reproduces the cleavage site of the class I
molecule (QTRA/GSHS). Also, the egfpC-primer encodes a
linker of five glycine residues to allow for flexibility between
the C-terminus of EGFP and the start of HLA-A2. The proof-
reading polymerase Pfu (Stratagene, La Jolla, CA) was used
for amplification in 30 cycles of [95/2, 55/3, 72/5]. The
resulting 0.7-kb band was excised and blunt-end cloned
into a holding vector bearing the hybrid cDNA K/A2. K/A2
consists of the mouse H2-K signal sequence fused with the
human HLA-A2 cDNA sequence. The construction of K/A2
is such that there is a NaeI site (GCC GGC) precisely at the
junction between the murine signal sequence and the A2
sequence. This NaeI site was used to accept the amplified
EGFP product, resulting in a EGFP/A2 fusion construct. This
cloning product was analyzed by DNA sequencing prior to
subcloning into the eukaryotic expression vector pCDNA3.1
(Invitrogen, Carlsbad, CA).
A mutant version of EGFP/A2 fusion protein was con-
structed in which the tyrosine residue in the cytoplasmic
tail was changed to alanine. This was accomplished by
using a PCR-based strategy described previously (Higu-
chi, 1990). The oligonucleotides used to make the 59
fragment were GCAGCTCAGACCACCAAGCACAAG-39
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The oligonucleotides used to make the 39 fragment were
59-TGCAGCCTGAGAGGCGCTCCCTCCTTTTCT-39 and 59-
TAGAAGGCACAGTCGAGG-39. The 39-most oligonucleo-
tide primer is contained within vector DNA. The resulting
mutant fragment was digested with XhoI and PmlI and
cloned back into the original EGFP/A2 expression plas-
mid. The resulting PCR generated construct was se-
quenced to ensure that only the intended alteration had
been made.
To create stable cell lines expressing EGFP/A2 or
CD4, 373 mg cells were transfected with individual ex-
pression vectors and selected in neomycin or puromycin.
Clonal and bulk cultures expressing high amounts of
GFP or CD4 were selected and used for experiments.
HIV infections. HIV expressing the marker gene PLAP
was made as described except that HXBePLAP was
pseudotyped with VSV-G protein (Chen et al., 1996; Col-
lins et al., 1998). HIV infections were conducted as fol-
lows: cells were treated with viral supernatant for ap-
proximately 24 h. Fresh media was added and cells were
allowed to incubate for 3 more days. Infected cells were
identified by expression of the PLAP marker.
Adenovirus constructs and transduction. A replication-
defective adenoviral vector expressing HIV-1 Nef was con-
structed by the vector core facility at the University of Mich-
igan essentially as described in Aoki et al., 1999 from the
shuttle vector pAdef-1aloxp provided by Dr. Gary Nabel.
he resultant replication-defective recombinant adenovirus
as deletions in the E2A, E1B, and E3 regions and expres-
ion of Nef in this construct was governed by the elongation
actor-1a promoter. The control virus (adenovector) is iden-
tical to adeno-Nef except that it lacks the Nef open reading
frame. A mutant version of adeno-Nef in which prolines 72
and 74 were replaced with alanine was constructed as
described previously (Higuchi, 1990). The oligonucleotides
used to make the 59 fragment were 59-CCCAAGCTTACC
ATGGGTGGCAAGT GGT CAAAA-39 and 59-CCAGTCACAG-
CTCAGGTAGCTTT AAGACCA-39. The oligonucleotides
used to make the 39 fragment were 59-TGGTCTTAAA GCTA-
CCTGAGCTGTGACTGG-39 and 59-CGGGATCCTCAGCAGT-
TCTTGAAG TACTCCGG-39. An adenovirus expressing this
mutant construct was made as described above for wild-
type Nef. The resulting PCR-generated constructs were
sequenced to ensure that only the intended mutation had
been made.
Adenovirus transductions were performed as follows:
373 mg cells were incubated with the indicated amount
of adenovirus in media containing DMEM plus 2% fetal
bovine serum. After 2–4 h an equal volume of fresh
DMEM plus 10% fetal bovine serum was added. Cells
were then incubated for 24–48 h prior to harvest.
Inhibition of PI 3-kinase. In experiments using
LY294002, the inhibitor or its solvent was added after the
first incubation period with adenovirus. Cells were as-
sayed approximately 18 h later. In Fig. 7, LY294002 wasobtained from RBI and was found not to affect Nef pro-
tein expression levels. Due to a lack of supply from this
manufacturer, LY294002 was subsequently obtained
from Upstate Biotechnology. This preparation had a
small effect on Nef protein expression levels which we
have compensated for by increasing the amount of virus
added to inhibitor-treated cells (Fig. 8 and Fig. 8 legend).
Matched controls consisting of adenovector alone were
included for all samples.
Analysis by fluorescence-activated cell sorting (FACS)
To detect cell surface EGFP/A2, cells were stained
with rabbit anti-GFP (Molecular Probes) and goat anti-
rabbit phycoerythrin (PE; 1:250; Caltag). To detect wild-
type HLA-A2 protein, cells were stained with murine
anti-HLA-A2 (1:200; One Lambda) and goat anti-mouse
PE (1:250; Caltag). To detect CD4, cells were stained with
an antibody directed against CD4 and directly conju-
gated to PE (Caltag). Analysis was performed on a Bec-
ton–Dickinson FACSCAN using Cellquest software.
Analysis by confocal microscopy
To detect GFP in HIV-infected or retrovirus-transduced
samples, cells were stained on microscope slides with
rabbit anti-PLAP (Biomeda, 1:500) and goat anti-rabbit-
Texas Red Conjugate (Molecular Probes) at a 1:250 di-
lution in wash buffer [phosphate buffered saline (PBS),
2% bovine calf serum, 10 mM HEPES, and 0.025% azide]
supplemented with Ca21 and Mg21. Following antibody
taining they were fixed with 2% paraformaldehyde in
ash buffer.
To detect GFP in 373 mg cells transduced with
deno-Nef or adenovector, cells were fixed with 2%
araformaldehyde in wash buffer (phosphate buffered
aline, 2% bovine calf serum, 10 mM HEPES, and
.025% azide). For Golgi staining, cells were stained
ith 24 nM BODIPY TR-ceramide (Molecular Probes)
n Ringer’s media on ice for 30 min followed by a 37°C
ncubation for 30 min. They were then rinsed and fixed
ith 2% paraformaldehyde in wash buffer. For con-A
taining, cells were stained with 40 mg/ml con-A–
Texas Red Conjugate (Molecular Probes) for 5 min on
ice, washed twice in PBS, and fixed with 2% parafor-
maldehyde. For transferrin staining, cells were treated
as described in Fig. 6A legend except that they were
incubated with transferrin Texas Red Conjugate at
37°C for 5 min, washed twice in PBS, and fixed with 2%
paraformaldehyde. All confocal analysis was per-
formed on a Bio-Rad MRC 600 confocal laser scanning
microscope. The images were converted to tagged
image file format (.tiff) using confocal assistant share-
ware and plates were prepared using Adobe Photo-
shop software.
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expression levels
Cells were lysed in NP40 lysis buffer (0.5% NP40, 50
mM Tris, pH 7.3, 5 mM MgCl2, 1 mM PMSF); protein
oncentration was determined using Pierce Coomassie
rotein Assay Kit, and equal amounts of protein were
oaded onto a 15% SDS–polyacrylamide gel. Protein was
lectroblotted onto Immobilon, blocked in 5% milk in TBS,
nd probed with HIV-1 Nef antiserum [obtained from the
IH AIDS Research and Reference Reagent Repository,
ivision of AIDS, NIAID, NIH, from Dr. Ronald Swanstrom
Shugars et al., 1993)] and/or antibody against dynamin-1
Affinity Bioreagents). Blots were developed using Super-
ignal (Pierce) according to the manufacturer’s instruc-
ions. To ensure that protein loading was equal, the
olyacrylamide gels were stained with Coomassie blue
ollowing electrophoretic transfer.
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